WHO ICTRP trial
Epirubicin for the Treatment of Sepsis & Septic Shock
CTIS2024-515776-12-00 · EU Clinical Trials Information System · Recruiting
Key facts
| Trial ID | CTIS2024-515776-12-00 |
|---|---|
| Public title | Epirubicin for the Treatment of Sepsis & Septic Shock |
| Scientific title | Epirubicin for the Treatment of Sepsis & Septic Shock - EPOS_ZKSJ0134 |
| Primary sponsor | Friedrich-Schiller-Universitaet Jena |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): No Therapeutic exploratory (Phase II): Yes Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | Germany |
| Conditions | Patients with sepsis or septic shock, currently hospitalized at the Intensive Care Unit (ICU) or Intermediate Care (IMC) regardless where the sepsis was first diagnosed.;Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses… |
| Interventions | Product Name: Epirubicin 50 mg HEXAL® Injektionslösung, 2 mg/ml, Product Code:PRD823269, Pharmaceutical Form: SOLUTION FOR INJECTION, Other descriptive name: , Strength: , Product Name: Isotonische Kochsalzlösung Fresenius, Product… |
| Registration date | Sep 19, 2024 |
| Target size | 45 |
| Secondary IDs | 2021-002300-12;01EN2001 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: